SUPERIOR SAFETY

TUNABLE IMMUNOGENICITY

Our first human PH I/II study has shown both numerically and less severe side effects compared to currently marketed products.

Our technology provides customizable immunogenicity.

High immune activation for vaccines
low immunogenicity to enable repeat dosing such as required for protein replacement

Adaptive LNP Platform

Our LNP technologies enable precise organ and cell targeting, with formulations for liver, spleen, lung, and inflamed tissues.

Our lipids can be tailored to degrade in the body under required conditions, improving biocompatibility, safety and activity

ORGAN & CELL SPECIFIC TARGETING

CONTROLLED BIODEGRADABILITY

OUR TECHNOLOGY

NeoVac has a broad portfolio of proprietary lipids advancing next-generation LNP technology to enable safer, adaptable mRNA therapeutics for vaccines, cancer immunotherapy, and autoimmune diseases